Trials on Lymphoma148

The following clinical trials are currently offered in Germany in this group.

148 matching trials

CHARLYActive, not recruiting

Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation

If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.

18–65 years · Relapsed / refractory · Phase II

CLL17Recruiting

CLL17

The CLL17 study directly compares therapies that are already well-established in the treatment of chronic lymphocytic leukemia (CLL).

18 years and older · First line · Phase III

GMALL 08/2013Recruiting

GMALL Registry Study

The GMALL Registry Study is an observational study of adult patients with a specific type of blood cancer (acute lymphoblastic leukemia, ALL).

18–55 years · Relapsed / refractory · Phase IV

LBL 2018Recruiting

Can a change in the current standard of care for lymphoblastic lymphoma in children (< 18 years) reduce the rate of disease recurrence involving the CNS?

Lymphoblastic lymphoma (LBL) is a malignant disease of the lymphatic system that primarily affects children and adolescents. The brain (CNS) can also be affected by LBL. The LBL2018 study is investigating whether a change to the current standard treatment protocol can reduce the risk of relapse involving the CNS. Children and adolescents under the age of 18 with newly diagnosed lymphoblastic lymphoma are eligible to participate in the study; no new drugs are being tested.

0–18 years · First line · Phase III

B-NHL 2013Recruiting

A study on the treatment protocol of the NHL-BFM and NOPHO Studien GruppenT for mature B-cell non-Hodgkin lymphoma and Burkitt leukemia in children and adolescents (B-NHL 2013)

Lymphomas and leukemias are malignant diseases of the blood cells that vary greatly in their presentation and prognosis. The aggressive subtypes spread rapidly and usually require prompt treatment, most often a combination of chemotherapy and an antibody. The goal of the B-NHL 2013 study is to investigate the efficacy of the antibody rituximab in addition to standard chemotherapy for aggressive mature B-cell non-Hodgkin lymphomas (B-NHL) and Burkitt leukemia (B-AL), and to compare it with the treatment currently in use. Patients who have been newly diagnosed with these diseases and are under 18 years of age are eligible to participate in the study.

0–18 years · First line · Phase III

AIEOP-BFM ALL 2017Recruiting

A More Targeted Approach to Leukemia: Less Chemotherapy, More Immunotherapy for Children and Adolescents with Acute Lymphoblastic Leukemia

Acute lymphoblastic leukemia (ALL) in children and adolescents is now very treatable thanks to intensive therapies. However, the medications used also carry a risk of side effects (toxicity). It is now also possible to accurately assess the severity and prognosis of ALL. The goal of the AIEOP-BFM ALL 2017 study is to make treatment more targeted and better tolerated—including through the use of immunotherapy with blinatumomab instead of highly toxic chemotherapy in high-risk patients. In addition, other targeted medications such as bortezomib and extended chemotherapy phases are used in certain subgroups to better prevent relapses. Patients up to 17 years of age with previously untreated ALL and certain subtypes are eligible to participate in this study.

0–17 years · First line · Phase III

INFORM RegistryRecruiting

INFORM Registry Study on Individualized Treatment for Patients with Recurrent Malignant Disease, with a Special Focus on Children and Adolescents

Many types of cancer can now be cured using modern treatment options. Nevertheless, relapses and progressive cancer remain a major challenge. The goal of the INFORM-REGISTER study is to use molecular genetic testing methods to gather information about tumor characteristics that can be used by treating physicians to inform future treatment decisions. Patients aged 0 to 40 with previously treated, treatment-resistant, or progressive cancer who no longer have any established curative treatment options available are eligible to participate in the study.

0–40 years · Relapsed / refractory · Phase IV

DALY 2-EURecruiting

DALY-2

The DALY-2 study aims to investigate whether, in patients with a relapse of an aggressive form of lymphoma (known as DLBCL), the body’s own modified immune cells (known as CAR-T cells) are more effective than chemotherapy.

18–70 years · Relapsed / refractory · Phase II

GOAL IIActive, not recruiting

GOAL II

The GOAL-II trial is investigating the efficacy of adding a new antibody to existing standard therapy in patients with relapsed aggressive lymphoma.

18–64 years · Relapsed / refractory · Phase II

frontMIND / MOR208C310Active, not recruiting

FRONTMIND

The FRONTMIND study is investigating whether adding an antibody (tafasitamab) and an immunomodulatory agent (lenalidomide) to the current standard of care improves treatment outcomes for aggressive lymphoma (B-NHL).

18–80 years · Phase III